Novavax (NVAX) Gross Margin: 2009-2025
Historic Gross Margin for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to 69.49%.
- Novavax's Gross Margin rose 4121.00% to 69.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.24%, marking a year-over-year increase of 2751.00%. This contributed to the annual value of 70.28% for FY2024, which is 523.00% up from last year.
- Per Novavax's latest filing, its Gross Margin stood at 69.49% for Q3 2025, which was down 23.85% from 91.24% recorded in Q2 2025.
- In the past 5 years, Novavax's Gross Margin ranged from a high of 100.00% in Q1 2021 and a low of -45.80% during Q2 2022.
- Over the past 3 years, Novavax's median Gross Margin value was 58.48% (recorded in 2024), while the average stood at 64.53%.
- In the last 5 years, Novavax's Gross Margin crashed by 14,580bps in 2022 and then skyrocketed by 13,266bps in 2023.
- Over the past 5 years, Novavax's Gross Margin (Quarterly) stood at 100.00% in 2021, then slumped by 5,086bps to 49.14% in 2022, then slumped by 234bps to 46.81% in 2023, then spiked by 1,167bps to 58.48% in 2024, then spiked by 4,121bps to 69.49% in 2025.
- Its Gross Margin was 69.49% in Q3 2025, compared to 91.24% in Q2 2025 and 97.88% in Q1 2025.